Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dihydroartemisinin + piperaquine + trimethoprim + sulfamethoxazole
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dihydroartemisinin-piperaquine + trimethoprim/sulfamethoxazole is a combination chemoprevention regimen evaluated for the prevention of malaria in HIV-infected pregnant women and their infants. The regimen combines dihydroartemisinin-piperaquine (DHA-PQ), an artemisinin-based combination therapy (ACT), with daily trimethoprim-sulfamethoxazole (TMP-SMX), which is the standard-of-care prophylaxis for HIV-infected individuals. Dihydroartemisinin generates reactive oxygen species that damage parasite proteins and membranes, while piperaquine interferes with heme detoxification. Trimethoprim and sulfamethoxazole act synergistically to inhibit folate synthesis by targeting dihydrofolate reductase and dihydropteroate synthase, respectively. This specific combination was studied in the Phase 3 PROMOTE Birth Cohort 2 trial (NCT02282293) sponsored by the University of California, San Francisco (UCSF) in Uganda.
- Other names
- dihydroartemisinin-piperaquine + trimethoprim-sulfamethoxazoledihydroartemisinin + piperaquine + trimethoprim + sulfamethoxazole
02
Targets
DHFR (Dihydrofolate reductase)HemeKCNH2 (Voltage-gated potassium channel subfamily H member 2)DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on dihydroartemisinin + piperaquine + trimethoprim + sulfamethoxazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dihydroartemisinin + piperaquine + trimethoprim + sulfamethoxazole.